RIGEL PHARMACEUTICALS INC 8-K

What Happened
Rigel Pharmaceuticals (RIGL) filed an 8-K on January 12, 2026 announcing that it has provided preliminary, unaudited estimated financial results for the fourth quarter and fiscal year ended December 31, 2025. The company released a press release titled “Rigel Provides Business Update and 2026 Outlook.” Rigel cautioned the estimates are based on currently available information and do not present all information necessary for a complete understanding of its financial condition or quarterly results.

Key Details

• Filing date: January 12, 2026 (Form 8-K).
• Period covered: preliminary, unaudited estimates for Q4 2025 and fiscal year ended December 31, 2025.
• Public disclosure: press release titled “Rigel Provides Business Update and 2026 Outlook” was attached to the filing.
• Company note: estimates are preliminary, unaudited and may change as final numbers and audited statements are prepared.

Why It Matters
This 8-K gives investors the company’s initial snapshot of recent quarterly and full‑year earnings trends (including revenue and other operating results once disclosed). Because the figures are preliminary and unaudited, they may be revised in the company’s upcoming audited financial statements or formal earnings release — so investors should treat these estimates as provisional and watch for the final report and any management commentary or guidance updates.